Integrated pharma maker of export-oriented Finished Dosage Forms and APIs (Atenolol, sterile Carbapenems, Cephalosporins, Macrolides) via Kopran Limited and its API subsidiary Kopran Research Laboratories.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 43 | 43 | 48 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 146 | 202 | 378 | 391 | 443 | 470 | 453 | 482 |
| Borrowings | 88 | 66 | 75 | 75 | 99 | 148 | 157 | 153 |
| Other Liabilities | 92 | 128 | 110 | 135 | 153 | 178 | 155 | 225 |
| Total Liabilities | 370 | 439 | 611 | 650 | 743 | 844 | 813 | 908 |
| AssetsFixed Assets | 111 | 112 | 151 | 165 | 182 | 208 | 235 | 346 |
| CWIP | 30 | 43 | 36 | 70 | 97 | 113 | 114 | 25 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 229 | 284 | 425 | 415 | 465 | 522 | 465 | 537 |
| Total Assets | 370 | 439 | 611 | 650 | 743 | 844 | 813 | 908 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 25 | 31 | 60 | -33 | 34 | 43 | 42 | 67 |
| Cash from Investing | -25 | -13 | -25 | -84 | -13 | -44 | -56 | -65 |
| Cash from Financing | -1 | -18 | -35 | 123 | -20 | 1 | 26 | -21 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -6 | 17 | 43 | -76 | -27 | -13 | -17 | 0 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (28.8×) and current (36.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -2.8% growth and a 29× exit, ₹194 only delivers your return if you pay ₹54. The price is currently baking in 22% growth.
EPS grows -2.8%/yr for 5 years, then fades to 6% over 2, exits at 29×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -2.8% | 5.18 |
| FY28 | -2.8% | 5.04 |
| FY29 | -2.8% | 4.89 |
| FY30 | -2.8% | 4.76 |
| FY31 | -2.8% | 4.62 |
| FY32 | 1.6% ·fade | 4.70 |
| FY33 | 6.0% ·fade | 4.98 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.